TTF1 and non-small cell lung carcinoma: Previous clinical studies have shown that pemetrexed-containing chemotherapy regimens in NSCLC have comparable efficacy for chemotherapy in patients with mutations in RET, ALK, ROS1 genes, and TTF-1 positive status (60, 61).